CRDL Valuation

Cardiol Therapeutics Inc

Add to Watchlist

Advanced Chart

1.080

-0.01(-0.917%)1D

Overview
Forecast
Valuation
Earnings

CRDL Relative Valuation

CRDL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRDL is overvalued; if below, it's undervalued.

Historical Valuation

Cardiol Therapeutics Inc (CRDL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.30. The fair price of Cardiol Therapeutics Inc (CRDL) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.08

Fair

-3.41

Trailing

Forward

-4.29

EV/EBITDA

Cardiol Therapeutics Inc. (CRDL) has a current EV/EBITDA of -4.29. The 5-year average EV/EBITDA is -3.82. The thresholds are as follows: Strongly Undervalued below -9.72, Undervalued between -9.72 and -6.77, Fairly Valued between -0.87 and -6.77, Overvalued between -0.87 and 2.09, and Strongly Overvalued above 2.09. The current Forward EV/EBITDA of -4.29 falls within the Historic Trend Line -Fairly Valued range.

-2.78

EV/EBIT

Cardiol Therapeutics Inc. (CRDL) has a current EV/EBIT of -2.78. The 5-year average EV/EBIT is -3.46. The thresholds are as follows: Strongly Undervalued below -11.02, Undervalued between -11.02 and -7.24, Fairly Valued between 0.32 and -7.24, Overvalued between 0.32 and 4.10, and Strongly Overvalued above 4.10. The current Forward EV/EBIT of -2.78 falls within the Historic Trend Line -Fairly Valued range.

0.00

Cardiol Therapeutics Inc. (CRDL) has a current PS of 0.00. The 5-year average PS is 25.53. The thresholds are as follows: Strongly Undervalued below -111.35, Undervalued between -111.35 and -42.91, Fairly Valued between 93.97 and -42.91, Overvalued between 93.97 and 162.42, and Strongly Overvalued above 162.42. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-7.30

P/OCF

Cardiol Therapeutics Inc. (CRDL) has a current P/OCF of -7.30. The 5-year average P/OCF is -6.03. The thresholds are as follows: Strongly Undervalued below -13.85, Undervalued between -13.85 and -9.94, Fairly Valued between -2.12 and -9.94, Overvalued between -2.12 and 1.79, and Strongly Overvalued above 1.79. The current Forward P/OCF of -7.30 falls within the Historic Trend Line -Fairly Valued range.

-6.09

P/FCF

Cardiol Therapeutics Inc. (CRDL) has a current P/FCF of -6.09. The 5-year average P/FCF is -6.29. The thresholds are as follows: Strongly Undervalued below -15.44, Undervalued between -15.44 and -10.86, Fairly Valued between -1.71 and -10.86, Overvalued between -1.71 and 2.86, and Strongly Overvalued above 2.86. The current Forward P/FCF of -6.09 falls within the Historic Trend Line -Fairly Valued range.

Cardiol Therapeutics Inc (CRDL) has a current Price-to-Book (P/B) ratio of 10.52. Compared to its 3-year average P/B ratio of 6.18 , the current P/B ratio is approximately 70.20% higher. Relative to its 5-year average P/B ratio of 5.54, the current P/B ratio is about 89.81% higher. Cardiol Therapeutics Inc (CRDL) has a Forward Free Cash Flow (FCF) yield of approximately -19.22%. Compared to its 3-year average FCF yield of -27.94%, the current FCF yield is approximately -31.22% lower. Relative to its 5-year average FCF yield of -22.46% , the current FCF yield is about -14.45% lower.

10.40

P/B

Median3y

6.18

Median5y

5.54

-19.85

FCF Yield

Median3y

-27.94

Median5y

-22.46

Competitors Valuation Multiple

The average P/S ratio for CRDL's competitors is 7.68, providing a benchmark for relative valuation. Cardiol Therapeutics Inc Corp (CRDL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CRDL.O

Cardiol Therapeutics Inc

Fate Therapeutics Inc

Forte Biosciences Inc

Loss

136.76M

ONCY.O

Oncolytics Biotech Inc

Loss

76.17M

Performance Decomposition

Market capitalization of CRDL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CRDL in the past 1 year is driven by Unknown.